Vejle Diabetes Biobank – a resource for studies of the etiologies of diabetes and its comorbidities

Abstract

AimsCarefully designed and established biobanks are considered one of the most essential resources to foster biomedical research as they provide cost-effective and rapid access to a vast variety of biological materials and related anthropometrics allowing for testing of various biomarkers as well as numerous original and pertinent bioclinical hypotheses related to human disease etiology and prognosis. The objective of the present study was to present the baseline data, design, and methods used for the establishment of the Vejle Diabetes Biobank. Further aims included assessment of the prevalence of diabetes and quality of diabetes treatment in a specified Danish region.MethodsThe Vejle Diabetes Biobank was established from 2007 to 2010 as a regional Biobank containing blood, DNA, and urine samples from patients with diabetes and a gender- and age-matched control population aged 25–75 years. Anthropometrics were obtained by physical examination, questionnaires, and interviews at the time of inclusion into the Biobank. The cohort was linked to the Danish Civil Registration System, the Danish National Patient Registry, and the Danish National Prescription Registry.ResultsIn total, 4,255 nondiabetic individuals and 3,320 patients with diabetes were included. Type 2 diabetes (T2D) patients had a higher body mass index (30 kg/m2) than type 1 diabetes (T1D) patients (25 and 26 kg/m2 in women and men, respectively) and control subjects (25 and 27 kg/m2 in women and men, respectively). Fasting levels of plasma triglycerides and blood pressure were higher in T2D patients (1.5 mmol/L and 148/85 mmHg, respectively) compared with T1D patients (0.9 mmol/L and 139/81 mmHg, respectively), whereas glycated hemoglobin (HbA1c), plasma high density lipoprotein, low density lipoprotein, and total cholesterol were lower in T2D patients (51 mmol/mol, 1.2 mmol/L, 2.2 mmol/L, and 4.2 mmol/L, respectively) compared with findings in T1D patients (61 mmol/mol, 1.6 mmol/L, 2.3 mmol/L, and 4.4 mmol/L, respectively). At the time of inclusion into the Biobank, 56% of the T2D patients and 25% of T1D patients had an HbA1c <7% (53 mmol/mol). Only 28% and 34% of the T2D patients, respectively, reached treatment target for blood pressure and lipids.ConclusionThe Vejle Diabetes Biobank represents one of the largest open diabetes case-control cohorts in Denmark. The Biobank invites collaborative investigations of diabetes and diabetes complication etiologies as well as studies of prognostic or predictive biomarkers.

Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study

“…The Vejle Diabetes Biobank cohort recruited patients aged between 25 and 75 years with type 2 diabetes from 31 December 2006 onwards (20). Patients with diabetes were identified using the Danish Personal Identification Number and the Danish Civil Registration System based on the presence of at least one of the following criteria: high glycated hemoglobin (HbA 1c ) value (one value of HbA 1c $6.6% [48.6 mmol/mol] in the laboratory database from 1996 to 2006), minimum three HbA 1c measurements in the laboratory database from 2002 to 2006, antidiabetic medication prescriptions in the Danish National Prescription Registry, and/or diabetes diagnosis registered in the Danish National Patient Registry (20). Furthermore, based on the results of the questionnaire administered on the day of the health examination, 57 patients selfreported type 2 diabetes (2%).…”

“…Data were derived from a questionnaire (covering smoking status, exercise habit, genetic disposition of diabetes, and antidiabetic medications and other medications), a health examination (including weight and height measurements to calculate BMI, and systolic and diastolic blood pressure measured with Omron M5 Professional [Osaka, Japan] in sitting position after a 5-min rest), biochemical measurements (HbA 1c , total cholesterol, HDL and LDL, C-reactive protein [CRP], albumin, and creatinine levels), and measurements of urinary 8-oxoGuo and 8-oxo-7,8-dihydro-29-deoxyguanosine (8-oxodG). In the Vejle Diabetes Biobank, 56% of the patients with type 2 diabetes received oral antidiabetics exclusively, 11% insulin alone, and 11% insulin combined with oral antidiabetics; 22% did not receive antidiabetic medication but did receive dietary and related lifestyle change advice (20). Additional information on the cohort and the full study protocol are available online (20).…”

“…In the Vejle Diabetes Biobank, 56% of the patients with type 2 diabetes received oral antidiabetics exclusively, 11% insulin alone, and 11% insulin combined with oral antidiabetics; 22% did not receive antidiabetic medication but did receive dietary and related lifestyle change advice (20). Additional information on the cohort and the full study protocol are available online (20). The biochemical measurements were analyzed using standard methods as previously described in the Vejle Diabetes Biobank (20).…”

“…Additional information on the cohort and the full study protocol are available online (20). The biochemical measurements were analyzed using standard methods as previously described in the Vejle Diabetes Biobank (20).…”

Cohort profile: the Funen Diabetes Database—a population-based cohort of patients with diabetes in Denmark

“…Denmark has a long tradition of registry-based diabetes research, and a few specific diabetes registries have been established, including the Danish Adult Diabetes Database, Vejle Diabetes Biobank and Danish Centre for Strategic Research in Type 2 Diabetes project cohort, which are described in detail elsewhere 6–8. The Funen Diabetes Database (FDDB) represents an important and detailed resource for diabetes research that can be of value in generating new knowledge.…”